LEADER 03260nam 2200625 a 450 001 9910785115703321 005 20230827225205.0 010 $a6612880457 010 $a1-282-88045-4 010 $a9786612880452 010 $a1-60750-609-2 035 $a(CKB)2670000000047230 035 $a(EBL)593778 035 $a(SSID)ssj0000441330 035 $a(PQKBManifestationID)12166145 035 $a(PQKBTitleCode)TC0000441330 035 $a(PQKBWorkID)10406820 035 $a(PQKB)11659473 035 $a(MiAaPQ)EBC593778 035 $a(Au-PeEL)EBL593778 035 $a(CaPaEBR)ebr10425042 035 $a(CaONFJC)MIL288045 035 $a(OCoLC)695394635 035 $a(EXLCZ)992670000000047230 100 $a20100721d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPulmonary arterial hypertension$b[electronic resource] $efocusing on a future : enhancing and extending life /$fedited by J. Antel, M.B. Hesselink and R.T. Schermuly 210 $aAmsterdam $cIOS Press$d2010 215 $a1 online resource (116 p.) 225 1 $aSolvay Pharmaceuticals Conferences ;$vv. 10 300 $aDescription based upon print version of record. 311 $a1-60750-601-7 320 $aIncludes bibliographical references and index. 327 $aTitle page; Preface; List of Contributors; Contents; Conference Preface; Surgical Treatment of Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: A Need for a More Focused Approach; Established and New Therapies for Hypoxia and Non-Hypoxia-Related Pulmonary Hypertension; Novel Anti-Proliferative Therapies in Pulmonary Hypertension; What Animal Models Tell Us About Treatments for Pulmonary Hypertension; Therapeutic Potential for Dual Inhibition of Endothelin Converting Enzyme and Neutral Endopeptidase in Pulmonary Arterial Hypertension 327 $aPulmonary Vascular Disease in the Newborn - From Pathophysiology to Therapeutic StrategiesFrom Concept to Therapy - Alternative Route of Drug Application: Inhalation; Author Index 330 $aPulmonary hypertension is a fatal lung and heart disease. It is characterized by shortness of breath, fatigue and fainting. It is exacerbated by an increase of the pressure in the lung vasculature through exercise, leading to progressive worsening of hemodynamics, right ventricular hypertrophy, right heart insufficiency and finally right heart failure. This book focuses on pulmonary arterial hypertension, a rare and progressive subgroup of pulmonary hypertension, which is today incurable and terminally fatal. Classification of pulmonary arterial hypertension, its pathology, and strategies for 410 0$aSolvay Pharmaceuticals Conferences ;$vv. 10. 606 $aPulmonary hypertension 615 0$aPulmonary hypertension. 676 $a616.1 676 $a616.1/32 701 $aAntel$b J$g(Jochen)$01499594 701 $aHesselink$b M. B$01499595 701 $aSchermuly$b R. T$01499596 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910785115703321 996 $aPulmonary arterial hypertension$93725728 997 $aUNINA